Experiencia clínica con el uso ambulatorio de tolvaptan. Costes y efectividad en nueve casos / Clinical experience with Tolvaptan outpatient use. Cost and effectiveness in 9 cases
Gac. méd. Méx
; 156(1): 78-81, ene.-feb. 2020. tab
Article
in Spanish
| LILACS
| ID: biblio-1249873
Responsible library:
BR1.1
RESUMEN
Resumen Introducción:
La introducción de tolvaptan ha supuesto la principal novedad en el tratamiento de la hiponatremia en los últimos años.Objetivo:
Describir la experiencia con tolvaptan en el Complejo Asistencial Universitario de León, España.Método:
Estudio observacional retrospectivo de utilización ambulatoria de tolvaptan en un hospital de tercer nivel, de marzo de 2014 a agosto de 2017.Resultados:
Fueron tratados con tolvaptan de forma ambulatoria nueve pacientes, 23.1 % alcanzó eunatremia en 24 horas. Posterior a la administración de tolvaptan se registró reducción en días de hospitalización (361 versus 70, p = 0.007), especialmente por hiponatremia (306 versus 49, p = 0.009).Conclusiones:
El uso a largo plazo de tolvaptan parece ser seguro y se relaciona con descenso en los días de hospitalización.ABSTRACT
Abstract Introduction:
Tolvaptan introduction has constituted the main therapeutic novelty in the management of hyponatremia in recent years.Objective:
To describe the experience with this drug at Complejo Asistencial Universitario de León, Spain.Method:
Retrospective, observational study of tolvaptan outpatient use in a tertiary care hospital from March 2014 to August 2017.Results:
A total of 9 patients were treated with tolvaptan in the outpatient setting. Eunatremia was reached in 24 h by 23.1%. After tolvaptan administration, a reduction in days of hospitalization was recorded (361 vs. 70; p = 0.007), especially in those days of hospitalization that were attributable to hyponatremia (306 vs. 49; p = 0.009).Conclusions:
Long-term use of tolvaptan appears to be safe and is associated with a decrease in days of hospitalization.
Full text:
Available
Collection:
International databases
Health context:
Sustainable Health Agenda for the Americas
Health problem:
Goal 4: Health financing
Database:
LILACS
Main subject:
Ambulatory Care
/
Antidiuretic Hormone Receptor Antagonists
/
Tolvaptan
/
Hyponatremia
Type of study:
Health economic evaluation
/
Observational study
/
Risk factors
Limits:
Aged
/
Aged, 80 and over
/
Female
/
Humans
/
Male
Country/Region as subject:
Europa
Language:
Spanish
Journal:
Gac. méd. Méx
Journal subject:
Medicine
Year:
2020
Document type:
Article
Affiliation country:
Spain
Institution/Affiliation country:
Complejo Asistencial Universitario de León/ES
/
Hospital Clínico Universitario/ES